Zymeworks (ZYME) Posts Revs of $1.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Zymeworks Reports Second Quarter 2017 Financial Results
August 8, 2017 4:01 PM EDTVANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Zymeworks) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the second quarter ended June 30, 2017.
During the second quarter, in addition to the completion of our initial public offering, we made significant progress on our clinical and partnered programs, said Ali Tehrani, Ph.D., Zymeworks President & CEO. We presented detailed dose escalation data at ASCO demonstrating safety and anti-tumor activity for ZW25. We also announced progress... More
